AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Why we are?
On the way to a Global Artificial Intelligence Champ
When we looked at the decision making landscape in organizations and observed that the available technologies and models were helping make decisions but with fixed cycles of information processing, running in batches, with little flexibility and agility.
Drug development process is...
Slow
~85%
from drug discovery to approval
Inefficient
~85%
of biomdical research is wasted
Risky
~90%
risk of failure in clinical trials
Key data challenges are...
Accessibility
Data is hidden in silos within organization
Ownership
Patients have no stake in use of their data
Insights
Pharma, Biotechs fail to access valuable healthcare data
How blockchain and AI can help us decipher medicine's big data
This video originally published on TED.
Mission & Vision
Mission
“Empowering our customers and partners with AI to develop newer, more efficacious therapies faster.”
Vision
“Building a universal treatment discovery engine for the untreatable diseases.”
Team Overview
Interdisciplinary Team
90
Data
Scientists
90
Software
Engineers
55%
Female
110
Medical
Experts
7
Commercial
45%
Male
Leadership Team
Holger Hoffmann
Chief Executive OfficerHolger Hoffmann is the Chief Executive Officer of Innoplexus. He brings with him over 25 years of broad international experience in Sales, Finance, Controlling, Joint Ventures, M&A, and Operations within management holdings, family-owned companies, and large industrial corporations.
Holger has the rare combination of experience in finance and sales, and due to his multilingual capability and genuine interest in diverse cultures and has developed excellent global business relationships.
Dr. Andreas Hochheimer
Chief Operating Officer & Chief Scientific OfficerAndreas Hochheimer is the Chief Operating Officer and Chief Scientific Officer of Innoplexus. Andreas’ ambition is to leverage Artificial Intelligence (AI) and Machine Learning (ML) to translate scientific knowledge into novel therapies to tackle so far incurable diseases and transform drug discovery and development from pipeline to market.
Andreas has over 25 years professional experience in Biotechnology and the Pharmaceutical Industry as well as internationally distinguished academic institutions and universities. Previously he held executive management and corporate leadership positions at BRAIN AG, Amgen and ISAR Bioscience.
Prof. Dr. Dr. Juergen Scheele
Chief Medical OfficerProf. Dr. Dr. Juergen Scheele is the Chief Medical Officer at Innoplexus and SVP Drug Development. He brings in over 20+ years of expertise in drug development and discovery. Prior to joining Innoplexus, Jürgen has held various senior positions such as Merck Global Clinical Development Leader for Tepotinib and other molecules, Global Development Leader at Roche Basel and Medical Director Micromet/ Amgen.
Jürgen has an extensive research background having received a PhD in Biochemistry / Molecular Biology from UC San Diego and the Salk Institute as well as a Master of Science in Chemistry from UC San Diego.
Dr. med. Werner Seiz
SVP – Translational ScienceWerner is the SVP – Translational Science at Innoplexus. He brings more than 28 years of expertise, primarily in early stage clinical development, biomarkers, bioimaging and drug safety evaluation.
His key expertise lies in clinical and pre-clinical studies for autoimmune diseases, cardiovascular, respiratory and renal indications as well as all kinds of ligand-binding assay development, validation and application.
Werner is an MD from Goethe University, Germany.
Gaurav Tripathi
Co-FounderGaurav Tripathi is a serial entrepreneur, co-founder, and Member of the Executive Board at Innoplexus AG and Board Member at Amrit AG
He studied at IIT Bombay and has 18+ years of experience across multiple startups working in Video, Big Data, Blockchain, and AI. He co-founded Innoplexus, now known as the “German AI champion in Life Sciences” working with top 30 Pharma companies globally. As CTO, he led the team to build an IP portfolio of 145+ patents (US/EU) in areas around AI, out of which 45 have him as an inventor.
Gaurav enjoys trekking, traveling, reading, and mentoring aspiring entrepreneurs and emerging startups.
Dr. Gunjan Bhardwaj
FounderGunjan is the Founder of Innoplexus and led the company as its CEO until 31st October 2022. He is an adjunct professor at Frankfurt School of Finance and management and Pforzheim University, Germany. He is an Ex BCG, EY who studied at IIT Bombay, MIT, Pforzheim University and European Business School. He has 18+ patents related to AI & Blockchain.
He published 2 books in Branding and Drug Discovery respectively as well as a number of publications in Harvard Business Review, Journal of Service Research, MIT Sloan Review etc. He received several awards including Capital – 40 under 40 award for Young Elite Award, Handelsblatt – BCG “Future Leaders of the new Reality“ and Top 30 “Thought Leader“ Award, Germany.
Amit Ananpara
Managing DirectorAI and Blockchain powered data analytics solutions that help the life science industry gain real-time access to relevant insights
Seasoned Professional with over 20 years in Business Strategy, P&L Accountability, Global Delivery Management, Product Engineering and Data Engineering
Supervisory Board
Ruben King-Shaw Jr.
Chairman, Supervisory BoardRuben King-Shaw Jr. has over three decades of executive leadership experience in the healthcare technology and private equity sectors and has held C-suite positions with leading private companies. He is a Chief Strategy Officer and Member of the Executive Committee of the Board of Steward Health, LLC since 2018. He is also a Chief executive officer of Mansa Equity Partners, Inc., a private equity and investment advisory firm specializing in supporting the growth of healthcare companies.
Mr. King-Shaw served on the Obama Administration’s Medicare Program Advisory and Oversight Committee.
Mohan Murti
Attorney & Counselor at LawAccomplished leader with over 40 years of successful experience in global business management. Demonstrated ability of revenue generation while promoting business strategy on an international basis – largely based in Europe.
Initially, nominated by the Ministry of Commerce, Government of India as India’s Representative to UNITED NATIONS-IPS, Paris and Zurich and since 1993, Director, Europe, CII, Cologne, Germany. Since 2004, Managing Director, Europe, Reliance Europe. Leadership Coach & Cross-Cultural Trainer noted for establishing team synergies.
Christina Pfaff-Benitez
Masters of Law (LL.M.)Christina Pfaff-Benitez, LL.M. studied in Passau, Boston and Frankfurt/M. and received her Master Degree in European Law and International Economics Law from the Johann Wolfgang Goethe University.
She wrote her thesis on Dispute Resolution in the WTO with grading summa cum laude. She was a private lecturer on European economic law at the University of Applied Sciences in Frankfurt/M. and a research assistant at the Chair for public Law and International Law of Prof. Dr. Dr. Rainer Hofmann and research fellow with the Merton Center for International Economic Order (cluster of excellence) with a research focus on international investment law.
Jayant Bhatt
Masters of Law (LL.M.)Mr. Bhatt holds dual Masters of Law (LL.M.)from New York University, USA & National University of Singapore and is a member of the prestigious Supreme Court Bar Association and Delhi High Court Bar Association. His office caters to varied clients comprising Governmental and Non-Governmental Bodies, Multinationals, Financial Institutions and individuals in an array of matters.
Mr Bhatt besides being a practicing Advocate is also a prolific speaker at various platforms and is an individual with firm belief in greater societal good. He has a keen interest in teaching and mentoring young minds and is an advisory board member to various organizations.
